About Us

Board of Directors

Distinguished and insightful leadership provides strategic guidance.
 

Board of Directors

Christopher S. Henney, Ph.D., D.Sc.

Chairman and Director
Cascadian Therapeutics Committee Membership: Compensation Committee, Corporate Governance and Nominating Committee

CHRISTOPHER S. HENNEY Ph.D., D.Sc. has served as the Chairman of our Board of Directors since September 2006 and as a member of our Board of Directors since March 2005. Previously Dr. Henney co-founded three major publicly held U.S. biotechnology companies, Immunex, ICOS and Dendreon, and held a seat on the board of directors and executive positions at each company. From 1995 to 2003, Dr. Henney was Chairman and Chief Executive Officer of Dendreon Corporation. Dr. Henney currently serves as a Vice-Chairman of the Board of Directors of Cyclacel Pharmaceuticals, a development-stage biopharmaceuticals company, as a member of the board of directors of Anthera Pharmaceuticals, Inc. a biopharmaceutical company and as a member of the board of directors of Prothena Corporation, a biotechnology company. Dr. Henney received a Ph.D. in experimental pathology from the University of Birmingham, England, where he also obtained his D.Sc. for contributions in the field of immunology. In 2012, Dr. Henney was elected to the Hall of Fame of the Association of International Biotechnology CEOs. Dr. Henney is a former professor of immunology and microbiology and has held faculty positions at Johns Hopkins University, the University of Washington and the Fred Hutchinson Cancer Research Center.

Return to Top >


Robert W. Azelby, M.B.A.

Director
Cascadian Therapeutics Committee Membership: Corporate Governance and Nominating Committee

Robert W. Azelby, M.B.A., has been a member of our Board of Directors since April 2017. Since November 2015, Mr. Azelby has served as the Executive Vice President, Chief Commercial Officer at Juno Therapeutics, Inc., a biotechnology company. Prior to joining Juno, Mr. Azelby was Vice President and General Manager, Oncology at Amgen Inc. from June 2012 to October 2015. From October 2010 to September 2012, he served as Amgen's Vice President, Amgen Oncology Sales. Prior to that, he served in various positions at Amgen, including Vice President, Commercial Effectiveness Unit and General Manager of Amgen Netherlands. Mr. Azelby received his B.A. in Economics and Religious Studies from the University of Virginia and M.B.A. from Harvard Business School.

Return to Top >


Gwen A. Fyfe, M.D.

Director

GWEN A. FYFE, M.D., has been a member of our Board of Directors since January 2016. Since 2009, Dr. Fyfe has been a consultant for venture capital firms and for a variety of biotechnology companies, and has been an invited member of Institute of Medicine panels, National Cancer Institute working groups and grant committees and American Society of Clinical Oncologists oversight committees. From 1997 to 2009, Dr. Fyfe held various positions with Genentech, Inc. (now a member of the Roche Group), including Vice President, Oncology Development; Vice President, Avastin® Franchise Team; as well as the honorary title of Senior Staff Scientist. Dr. Fyfe played an important role in the development of Genentech's approved oncology agents including Rituxan®, Herceptin®, Avastin® and Tarceva®. Dr. Fyfe sat on the development oversight committee for all of Genentech's products and participated in the Research Review Committee that moved products from research into clinical development. Currently Dr. Fyfe serves on the boards of Array Biopharma Inc. and Infinity Pharmaceuticals, Inc. Dr. Fyfe is a graduate of Washington University School of Medicine and a board certified pediatric oncologist.

Return to Top >


Steven P. James

Director
Cascadian Therapeutics Committee Membership: Audit Committee, Compensation Committee

STEVEN P. JAMES has been a member of our Board of Directors since February 2015. Mr. James served as President and Chief Executive Officer of Labrys Biologics, Inc., from December 2012 until its acquisition by Teva Pharmaceuticals in July 2014. He was President and Chief Executive Officer of KAI Pharmaceuticals, Inc., from October 2004 until its acquisition by Amgen in July 2012. He was Senior Vice President, Commercial Operations, at Exelixis, Inc., from 2003 until 2004. Previously he held senior business roles at Sunesis Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc. He began his career in new product planning at Eli Lilly and Company. Mr. James is also a member of the board of directors of Ocera Therapeutics, Inc., and Chrono Therapeutics. Mr. James earned a Bachelor of Arts degree in biology from Brown University and a Masters in Management degree from the Kellogg Graduate School of Management at Northwestern University.

Return to Top >


Ted W. Love, M.D.

Director
Cascadian Therapeutics Committee Membership: Audit Committee, Compensation Committee

TED. W. LOVE, M.D., has been a member of our Board of Directors since September 2013. Since June 2014, Dr. Love has served as Chief Executive Officer of Global Blood Therapeutics, Inc. From February 2010 to August 2012, Dr. Love served as Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc. From 2001 to January 2009, Dr. Love served as Chairman and Chief Executive Officer of Nuvelo, Inc. Dr. Love joined Nuvelo from Theravance, Inc., where he served as Senior Vice President of Development from 1998 to 2001. Previously, he spent six years at Genentech, Inc., where he held a number of senior management positions in medical affairs and product development and served as chairman of Genentech's Product Development Committee. Dr. Love also serves as a member of the boards of directors of biopharmaceutical companies Amicus Therapeutics, Inc. and Kalobios Pharmaceuticals, Inc. Until April 2012, he served on the California Independent Citizens' Oversight Committee. Dr. Love earned his Bachelor of Science in molecular biology from Haverford College and his M.D. from Yale Medical School.

Return to Top >


Scott D. Myers

Director, President and CEO
Cascadian Therapeutics Inc.

SCOTT D. MYERS has served as our President, Chief Executive Officer and been a member of our Board of Directors since April 2016. Prior to joining Cascadian Therapeutics, Mr. Myers served as the Chief Executive Officer of Aerocrine AB, life sciences company, from September 2011 until it was acquired by Circassia Pharmaceuticals plc in July 2015. From January 2007 to August 2011, Mr. Myers served as a Vice President of UCB S.A., a biopharmaceutical company. In this role, Myers oversaw commercial operations and medical affairs for 32 countries in the EU. From December 2005 to January 2007, Mr. Myers served as the Chief Commercial Officer for DOV Pharmaceutical, a development stage pharmaceutical company, and from 2000 to 2005, Mr. Myers held several senior positions at Johnson & Johnson including Senior Vice President and General Manager. Additionally, from April 2012 to April 2014, Mr. Myers served as a member of the board of directors of Orexo AB, a pharmaceutical company and is currently an Industry Advisor for EQT, an investment fund. Mr. Myers received his Bachelor of Arts degree in biology from Northwestern University and M.B.A from the Graduate School of Business from the University of Chicago.

Return to Top >


Daniel K. Spiegelman, M.B.A.

Director
Cascadian Therapeutics Committee Membership: Audit Committee, Corporate Governance and Nominating Committee

DANIEL K. SPIEGELMAN, M.B.A. has been a member of our Board of Directors since June 2008. Mr. Spiegelman was appointed executive vice present and chief financial officer of BioMarin Pharmaceuticals in May 2012. From October 2009 until May 2012, Mr. Spiegelman served as a consultant to provide strategic financial support to a portfolio of public and private life sciences companies. From 1998 to 2009, Mr. Spiegelman was employed at CV Therapeutics, Inc., a biopharmaceutical company, most recently as senior vice president and chief financial Officer. From 1992 to 1998, Mr. Spiegelman was an employee at Genentech, Inc., a biotechnology company, serving most recently as treasurer. Mr. Spiegelman also serves as a member of the board of directors of Relypsa, Inc., a development-stage biopharmaceutical company. Mr. Spiegelman received his B.A. and M.B.A. from Stanford University.

Return to Top >